StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
StockVaultSandbox
ScreenerSectorsLearnMethodDesign
Request access
Back to screenerCompare

PFIZER — PFIZER LTD

Price History

Data as of 26 Jun 2026· via fincrux

How PFIZER has traded over time.

Is the price reasonable right now?

Where today's price sits within its own 12-month range — context, not advice.

Lower end of its 12-month range3% of range

Trading about 23% below its 12-month high — historically cheaper territory for this stock. It sits below its 200-day average, the longer-term trend.

₹4,422 low₹5,767 high
vs 50-day avg
−4.3%
vs 200-day avg
−8.9%
Beginner mode
Plain English, with everything explained

PFIZER

NSE

PFIZER LTD

Healthcare / Pharma

₹4,460.70
0.00%
last close
0%
Quality Score
Looks high-qualityBig money steady

PFIZER LTD clears 2 of 3 of our quality checks. By the numbers, it looks like a sturdy, well-run business at a fair price. Still your call — but this is the kind of company that doesn't rely on hype.

Company size
₹21037.00 Cr
Price tag
27.7×
Money it earns
18.0%

The four quality checks

Every company faces the same four checks. Tap the ? on any term to learn what it means.

01

Is the company drowning in loans?

We check how much the company has borrowed versus its own money. Too much debt makes a business fragile when times get tough.

Aligned

The company keeps its borrowing under control. That's a sign of a sturdy balance sheet.

D/E 0.02goal < 0.5
02

Does it make good money, consistently?

We look at how much profit the company squeezes out of its owners' money, averaged over three years — not just one lucky quarter.

Aligned

It turns its money into healthy profits year after year. A hallmark of a quality business.

ROE 18.0%goal > 15% (3y avg)
03

Is the big, smart money buying in?

Large professional investors (global funds and Indian mutual funds) do deep research before buying. We track whether they've been adding or trimming their stake.

Watch

Big investors are roughly holding their position, neither rushing in nor out.

FII+DII 19.7%goal stable or rising (2Q)
04

Is the price reasonable right now?

Even a great company can be a bad buy if it's overpriced. We compare today's price tag to how this company has typically been priced over the past five years.

No data

We don't have enough reliable data to run this check yet, so we're leaving it open rather than guessing.

Data unavailablegoal P/E < 5y median

What we noticed

Observations from the data — not recommendations.

  • Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers ba…
Data as of 26 Jun 2026· via fincrux

StockVault is an educational research and mathematical-modeling sandbox. It presents structural readings derived from public data and does not provide investment advice, recommendations, or target prices. Figures shown are illustrative and delayed. Markets carry risk; decisions are your own.

Balance Sheet

What PFIZER owns and owes over the years. Tap the ? on any line to learn what it means.

Line itemFigures in ₹ crore
ItemMar '22Mar '23Mar '24Mar '25Mar '26
Borrowings3941404170
Equity Capital4646464646
Reserves2,8193,1623,5504,1724,157
Total Assets3,9014,0014,2294,9114,922
Total Liabilities3,9014,0014,2294,9114,922

Borrowings rising

Total borrowings are up about 79% over the last 5 years — worth watching alongside how much it earns.

Periodic Performance

Yearly net profit for PFIZER — does it earn money consistently?

Potential turnaroundPotential turnaround (pattern in the data)

Profit dipped in the middle years and has been recovering in the most recent ones. That's a pattern in the data, not a forecast.

₹613 Cr
₹624 Cr
₹551 Cr
₹768 Cr
₹722 Cr
Mar '22Mar '23Mar '24Mar '25Mar '26
rev ₹2,611 Crrev ₹2,425 Crrev ₹2,193 Crrev ₹2,281 Crrev ₹2,520 Cr
Net profit · annualProfitLoss

Strengths & Risks

What the numbers say is good and bad about PFIZER — observations, not recommendations.

Strengths

4
  • Turns owners' money into healthy profits, year after year.
  • Keeps borrowing low relative to its own capital — a sturdy balance sheet.
  • Recent results show a return to profit after weaker years — a turnaround pattern in the data.
  • Sits in the lower part of its 12-month range — historically cheaper territory for this stock.

Risks

0

No notable risks flagged by the numbers right now.

Institutional Ownership Trend

FII and DII holding across the last four quarters.

FII· Foreign institutions
2.8%+0.4 pp
DII· Domestic institutions
16.9%-0.3 pp
Jun '25Sep '25Dec '25Mar '26

Sector Peers

How others in Healthcare / Pharma score on the same four guardrails.

  • DIVISLABDIVI S LABORATORIES LTD100
  • ALKEMALKEM LABORATORIES LTD.100
  • ZYDUSLIFEZYDUS LIFESCIENCES LTD100
  • IPCALABIPCA LABORATORIES LTD100
  • AJANTPHARMAJANTA PHARMA LIMITED100
View the full sector